Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Issue 12 (28th September 2017)

• Record Type: Journal Article
• Authors: Lv, Yong; Qi, Xingshun; He, Chuangye; Wang, Zhengyu; Yin, Zhanxin; Niu, Jing; Guo, Wengang; Bai, Wei; Zhang, Hongbo; Xie, Huahong; Yao, Liping; Wang, Jianhong; Li, Tao; Wang, Qiuhe; Chen, Hui; Liu, Haibo; Wang, Enxing; Xia, Dongdong; Luo, Bohan; Li, Xiaomei; Yuan, Jie; Han, Na; Zhu, Ying; Xia, Jielai; Cai, Hongwei; Yang, Zhiping; Wu, Kaichun; Fan, Daiming; Han, Guohong
• Is Part Of: Gut. Volume 67:Issue 12(2018)
• Page Start: 2156
• Page End: 2168
• Publication Date: 2017-09-28
• Subjects: endoscopy -- liver Cirrhosis -- portal hypertension -- venous thrombosis -- interventional radiology; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2017-314634
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: Limited data are available on the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis (PVT). This study aimed to compare transjugular intrahepatic portosystemic shunt (TIPS) with covered stents versus endoscopic band ligation (EBL) plus propranolol for the prevention of variceal rebleeding among patients with cirrhosis and PVT. Design: Consecutive cirrhotic patients (94% Child-Pugh class A or B) with PVT who had variceal bleeding in the past 6 weeks were randomly assigned to TIPS group (n=24) or EBL plus propranolol group (EBL+drug, n=25), respectively. Primary endpoint was variceal rebleeding. Secondary endpoints included survival, overt hepatic encephalopathy (OHE), portal vein recanalisation and rethrombosis, other complications of portal hypertension and adverse events. Results: During a median follow-up of 30 months in both groups, variceal rebleeding was significantly less frequent in the TIPS group (15% vs 45% at 1 year and 25% vs 50% at 2 years, respectively; HR=0.28, 95% CI 0.10 to 0.76, p=0.008), with a significantly higher portal vein recanalisation rate (95% vs 70%; p=0.03) and a relatively lower rethrombosis rate (5% vs 33%; p=0.06) compared with the EBL+drug group. There were no statistically significant differences in survival (67% vs 84%; p=0.152), OHE (25% vs 16%; p=0.440), other complications of portal hypertension and adverse events between groups. Conclusion: Covered TIPS placement in patients with PVT and moderately decompensated cirrhosis was more effective than EBL combined with propranolol for the prevention of rebleeding, with a higher probability of PVT resolution without increasing the risk of OHE and adverse effects, but this benefit did not translate into improved survival. Trial registration number: ClinicalTrials.gov: NCT01326949 .